Clinical Trial Update: Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma. [Phase 3]

View source ↗

Summary

Novartis reports the completion of a Phase 3 long-term study of the investigational asthma agent IGE025 in adults with moderate-to-severe asthma. The trial stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• IGE025

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 3 | Status: COMPLETED